US006350729B1

(12) **United States Patent**
Kilbourn et al.

(10) **Patent No.: US 6,350,729 B1**
(45) **Date of Patent: *Feb. 26, 2002**

(54) **INHIBITION OF NITRIC OXIDE-MEDIATED HYPOTENSION AND SEPTIC SHOCK WITH IRON-CONTAINING HEMOPROTEIN**

(75) Inventors: **Robert G. Kilbourn**, Houston, TX (US); **Joseph De Angelo**, Hamtramck, MI (US); **Joseph Bonaventura**, Beaufort, NC (US)

(73) Assignees: **Board of Regents, The University of Texas System**, Austin, TX (US); **Apex Bioscience, Inc.**, Research Triangle Park; **Duke University**, Durham, both of NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/615,353**

(22) Filed: **Jul. 13, 2000**

Related U.S. Application Data

(63) Continuation of application No. 09/204,392, filed on Dec. 2, 1998, now Pat. No. 6,103,690, which is a continuation of application No. 08/942,632, filed on Oct. 2, 1997, now Pat. No. 5,900,403, which is a continuation of application No. 08/184,255, filed on Jan. 18, 1994, now Pat. No. 5,674,836, which is a continuation of application No. 07/838,603, filed on Feb. 19, 1992, now Pat. No. 5,296,466.

(51) **Int. Cl.**[7] **A61K 38/42**

(52) **U.S. Cl.** **514/6**; 514/12; 514/21; 424/85.2; 530/385

(58) **Field of Search** 514/6, 12, 21; 424/85.2; 530/385

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,061,736	A	12/1977	Morris et al.	424/177
4,584,130	A	4/1986	Bucci et al.	260/112
4,598,064	A	7/1986	Walder	514/6
4,751,068	A	6/1988	Bickar et al.	423/437
5,028,627	A	7/1991	Kilbourn et al.	514/565
5,082,642	A	1/1992	Bickar et al.	423/402
5,296,466	A	3/1994	Kilbourn et al.	514/6
5,334,706	A	8/1994	Przybelski	530/385
5,480,866	A	1/1996	Bonaventura et al.	514/6
5,510,464	A	4/1996	Przybelski	530/385
5,674,836	A	10/1997	Kilbourn et al.	514/6
5,900,403	A *	5/1999	Kilbourn et al.	514/6
6,103,690	A *	8/2000	Kilbourn et al.	514/6

FOREIGN PATENT DOCUMENTS

WO	91/04024	4/1990
WO	90/02654	7/1990
WO	91/04023	4/1991
WO	91/84023	4/1991
WO	93/00893	1/1993

OTHER PUBLICATIONS

Aisaka et al., "N^G–Methylarginine,an Inhibitor of Endothelium–DerivedNitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in Vivo?" *Biochemical and Biophysical Research Communications*, 160(2):881–886, 1989.

Aranow et al., "Effect of Human Hemoglobin on Systemic and Regional Hemodynamics in a Porcine Model of Endotoxemic Shock," *Crit. Care Med.*, 2495):807–814, 1996.

Baur, "The Evolution of Methaemalbumin," *Comp. Biochem. Physiol.*, 30:657–664, 1969.

Bickar et al., "Carbon Monoxide–Driven Reduction of Ferric Heme and Heme Proteins," *Journal of Biological Chemistry*, 259(17):10777–10783, 1984.

Bone, "A Critical Evaluation of New Agents for the Treatment of Sepsis," *JAMA* 266(12):1686–1691, 1991.

Bone et al., "Comparison of Different Doses of Pyridoxalatedhemoglobin Polyethylene Conjugate in the Treatment of Hyperdynamic Sepsis," *Society of Critical Care Medicine Conference*, New Orleans, Feb.5–9, 1996.

Bone et al., "Effects of Nitric Oxide Scavenging on Sheep Pancreas and Liver During Sepsis," *Experimental Biology '96, Annual meeting of professional Research Scientists*, Washington, D.C., Apr. 14–17, 1996.

Bone et al., "Hemodynamic Effects of Nitric Oxide Synthase Inhibition and Nitric Oxide Scavenging in Endotoxemic Sheep," *International Anesthesia Research Society, 71st Clinical and Scientific Congress*, San Francisco, California, Mar. 14–18, 1997.

Bone et al., "Hemodynamic Effects of Pyridoxalated Hemoglobin Polyoxyethylene Conjugate (PHP) in Conscious Sheep During Septic Shock," *American Society of Anesthesiologist*, Atlanta, 1995.

Bone et al,, "Nitric Oxide Synthase Inhibition Versus Nitric Oxide Scavenging in Sepsis," *68th Scientific Sessions of the American Heart Association*, Anaheim, California, Nov. 13–16, 1995.

Bone, "The Pathogenesis of Sepsis," *Ann. Int. Med.* 115:457–469, 1991.

Bonkovsky et al., "Intravenous Heme–Albumin in Acute Intermittent Prophyria: Evidence for Repletion of Depatic Hemoproteins and Regulatory Heme Pools," *The American Journal of Gastroenterology*, 86(8):1050–1056, 1991.

(List continued on next page.)

Primary Examiner—Chhaya D. Sayala
(74) *Attorney, Agent, or Firm*—Fulbright & Jaworski LLP

(57) **ABSTRACT**

The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.

16 Claims, 1 Drawing Sheet